ES2173057T1 - Preparacion de la forma cristalina ii de la claritromicina. - Google Patents

Preparacion de la forma cristalina ii de la claritromicina.

Info

Publication number
ES2173057T1
ES2173057T1 ES97934319T ES97934319T ES2173057T1 ES 2173057 T1 ES2173057 T1 ES 2173057T1 ES 97934319 T ES97934319 T ES 97934319T ES 97934319 T ES97934319 T ES 97934319T ES 2173057 T1 ES2173057 T1 ES 2173057T1
Authority
ES
Spain
Prior art keywords
methylerythromycin
alkyl
solvent
halo
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES97934319T
Other languages
English (en)
Other versions
ES2173057T3 (es
Inventor
Jih-Hua Liu
David A Riley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27102712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2173057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/681,695 external-priority patent/US5844105A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of ES2173057T1 publication Critical patent/ES2173057T1/es
Application granted granted Critical
Publication of ES2173057T3 publication Critical patent/ES2173057T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN PROCEDIMIENTO DE PREPARACION DE LA FORMA II DE LA 6 - O - METILERITROMICINA A. DICHO PROCEDIMIENTO CONSISTE EN CONVERTIR ERITROMICINA A EN 6 - O - METILERITROMICINA A Y TRATAR ESTA ULTIMA CON CIERTO NUMERO DE DISOLVENTES ORGANICOS COMUNES O MEZCLAS DE LOS MISMOS.
ES97934319T 1996-07-29 1997-07-28 Preparacion de la forma ii cristalina de claritromicina. Expired - Lifetime ES2173057T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/681,695 US5844105A (en) 1996-07-29 1996-07-29 Preparation of crystal form II of clarithromycin
US681695 1996-07-29
US90027197A 1997-07-25 1997-07-25
US900271 1997-07-25

Publications (2)

Publication Number Publication Date
ES2173057T1 true ES2173057T1 (es) 2002-10-16
ES2173057T3 ES2173057T3 (es) 2004-11-16

Family

ID=27102712

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97934319T Expired - Lifetime ES2173057T3 (es) 1996-07-29 1997-07-28 Preparacion de la forma ii cristalina de claritromicina.

Country Status (12)

Country Link
EP (1) EP0915899B1 (es)
JP (4) JP4104660B2 (es)
KR (1) KR100524214B1 (es)
AT (1) ATE272646T1 (es)
AU (1) AU733646B2 (es)
CA (1) CA2261732C (es)
DE (3) DE29724846U1 (es)
DK (1) DK0915899T3 (es)
ES (1) ES2173057T3 (es)
IL (1) IL127833A (es)
PT (1) PT915899E (es)
WO (1) WO1998004574A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
CA2245398C (en) 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR20010008496A (ko) * 1999-07-01 2001-02-05 유충식 6-오-메틸 에리트로마이신의 제조방법
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
PT1254146E (pt) * 1999-12-16 2005-10-31 Teva Pharma Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
PL356645A1 (en) 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
AU2578701A (en) 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
CN1193036C (zh) * 2000-03-15 2005-03-16 韩美药品工业株式会社 制备甲红霉素－克拉霉素ⅱ型晶体的方法
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
KR100361397B1 (ko) * 2000-03-15 2002-11-23 한미약품공업 주식회사 에리스로마이신 에이 9-오-트로필옥심 유도체를 이용한클라리스로마이신의 제조방법
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
EP1671979B1 (en) * 2001-05-22 2008-08-13 Pfizer Products Inc. New Cristal Form of Azithromycin
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
IL158591A0 (en) * 2001-05-22 2004-05-12 Pfizer Prod Inc Crystal forms of azithromycin
KR100372254B1 (en) * 2002-07-15 2003-02-19 Korea United Pharm Inc Erythromycin a 9-o-pseudosaccharinyl oxime derivative and process for preparing clarithromycin using the same
AU2003271408B2 (en) * 2002-12-31 2008-07-17 Alembic Limited A process for the purification of roxithromycin
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
ES2401467T3 (es) * 2006-12-05 2013-04-19 Bristol-Myers Squibb Company Polimorfos de motilida
DE102007016367A1 (de) * 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572298A (en) * 1980-06-04 1982-01-07 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
JP2782793B2 (ja) * 1988-06-15 1998-08-06 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives

Also Published As

Publication number Publication date
KR20000029591A (ko) 2000-05-25
JP2002514171A (ja) 2002-05-14
JP2013151542A (ja) 2013-08-08
IL127833A0 (en) 1999-10-28
ES2173057T3 (es) 2004-11-16
DE29724846U1 (de) 2004-12-16
KR100524214B1 (ko) 2005-11-01
DE97934319T1 (de) 2004-08-26
CA2261732A1 (en) 1998-02-05
PT915899E (pt) 2004-11-30
IL127833A (en) 2004-06-20
DE69730138D1 (de) 2004-09-30
EP0915899B1 (en) 2004-08-04
JP2009242411A (ja) 2009-10-22
WO1998004574A1 (en) 1998-02-05
DE69730138T2 (de) 2005-03-03
JP4104660B2 (ja) 2008-06-18
ATE272646T1 (de) 2004-08-15
JP2006137765A (ja) 2006-06-01
EP0915899A1 (en) 1999-05-19
AU733646B2 (en) 2001-05-17
CA2261732C (en) 2001-07-24
AU3740597A (en) 1998-02-20
DK0915899T3 (da) 2004-11-29

Similar Documents

Publication Publication Date Title
PT915899E (pt) Preparacao da forma cristalina ii da eritromicina
AU526571B2 (en) Alkyl derivatives of c-076 compounds
KR850007434A (ko) 에리트로마이신a 유도체의 선택적 메틸화 방법
AU3172893A (en) 5-O-desosaminylerythronolide derivatives
ATE119905T1 (de) Makrolide antibiotika und verfahren zu deren herstellung.
CA2183453A1 (en) Antiparasitic Agents
DE69413393D1 (de) In 15-stellung substituierte 4-azasteroide
KR910019994A (ko) 시클로헥센온 옥심 에테르, 이들의 제조방법, 이들의 제조를 위한 중간체 및 이들의 제초제로서의 용도
EA200201016A1 (ru) Способ получения кристаллической формы i каберголина
DK1133511T3 (da) Hidtil ukendte mellemprodukter, fremgangsmåde til fremstilling af makrolidantibiotikum derudfra
EP0704425A4 (en) ADDITIVE FOR LUBRICANTS AND OIL, LUBRICANT AND OIL COMPOSITIONS CONTAINING IT AND NEW SUBSTITUTED HYDROXY-AROMATIC ESTER DERIVATIVE
MX9301721A (es) Derivados, composiciones de carbinol de bis-arilo sin puente, y metodos de uso.
KR940009192A (ko) 세팔로스포린 유도체 및 그의 제조방법
DE60005565D1 (de) Reinigung einer metallorganischen verbindung durch umkristallisieren
DE3165998D1 (de) Indole and indoline derivatives
ES8506011A1 (es) Procedimiento para la obtencion de un derivado de tetrahidrobenzotiazol
KR930010014A (ko) 기론다론 화합물 및 그의 제조방법
DE60131253D1 (de) 6-oxygenierte steroid-estrogene mit aromatischen a- und b-ringen
RU2000113199A (ru) Способ получения производных 2-аминотиазолкарбоксамида
EP1310248A4 (en) PHARMACEUTICAL COMPOSITION
IE801888L (en) Trans-fused decahydroquinolinol derivatives
JPS54154739A (en) Reducing agents
ES417883A1 (es) Procedimiento para la preparacion de derivados de bifenilo.
KR970074771A (ko) 지네로부터 추출한 신규한 퀴놀론계 화합물 및 그 유도체
KR970014569A (ko) 치환된 아미노기를 갖는 신규 티아졸에톡시퀴나졸린 유도체, 그의 제조방법 및 그를 유효성분으로 하는 식물 병원균 퇴치용 농약 조성물